| NCT04000594 |
A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT04000594 |
Recruiting |
Hoffmann-La Roche |
2021-02-17 |
| NCT04102579 |
Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease |
https://ClinicalTrials.gov/show/NCT04102579 |
Recruiting |
Neurocrine Biosciences |
2021-03-31 |
| NCT03344601 |
PHysical Activity and Exercise Outcomes in Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT03344601 |
Active, not recruiting |
Cardiff University |
2020-04-30 |
| NCT03342053 |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington’s Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139) |
https://ClinicalTrials.gov/show/NCT03342053 |
Completed |
Hoffmann-La Roche |
2019-10-08 |
| NCT03306888 |
Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People With Premanifest and Early Stage HD |
https://ClinicalTrials.gov/show/NCT03306888 |
Completed |
Teachers College, Columbia University |
2019-04-01 |
| NCT03252535 |
Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT03252535 |
Active, not recruiting |
Azidus Brasil |
2022-01-31 |
| NCT03233646 |
OCTA in Mild Cognitive Impairment and Alzheimer’s Disease |
https://ClinicalTrials.gov/show/NCT03233646 |
Recruiting |
Duke University |
2021-04-01 |
| NCT03225846 |
Safety and Tolerability of WVE-120102 in Patients With Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT03225846 |
Recruiting |
Wave Life Sciences Ltd. |
2020-12-31 |
| NCT03225833 |
Safety and Tolerability of WVE-120101 in Patients With Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT03225833 |
Recruiting |
Wave Life Sciences Ltd. |
2020-12-31 |
| NCT03193099 |
Decoding Presymptomatic White Matter Changes in Huntington Disease |
https://ClinicalTrials.gov/show/NCT03193099 |
Completed |
Institut National de la Santé Et de la Recherche Médicale, France |
2019-12-30 |
| NCT03019289 |
A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT03019289 |
Completed |
Prilenia |
2018-02-09 |
| NCT02990676 |
Exploring Computerised Cognitive Training for People With Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT02990676 |
Completed |
Cardiff University |
2019-03-13 |
| NCT02956148 |
Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers |
https://ClinicalTrials.gov/show/NCT02956148 |
Completed |
CHDI Foundation, Inc. |
2017-10-05 |
| NCT02926820 |
Working Memory Training in Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT02926820 |
Completed |
York University |
2016-03-31 |
| NCT02876445 |
Caregiver Burden in Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT02876445 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2016-03-31 |
| NCT02750982 |
Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases. |
https://ClinicalTrials.gov/show/NCT02750982 |
Completed |
Brown, Theodore R., M.D., MPH |
2018-08-31 |
| NCT02728115 |
Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT02728115 |
Active, not recruiting |
Azidus Brasil |
2022-10-31 |
| NCT02535884 |
Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington’s Disease (HD) |
https://ClinicalTrials.gov/show/NCT02535884 |
Recruiting |
Heinrich-Heine University, Duesseldorf |
2020-06-30 |
| NCT02519036 |
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT02519036 |
Completed |
Ionis Pharmaceuticals, Inc. |
2017-11-08 |
| NCT02509793 |
A Pilot Study Assessing Impulsivity in Patients With Huntington’s Disease on Xenazine (Tetrabenazine) |
https://ClinicalTrials.gov/show/NCT02509793 |
Recruiting |
The Methodist Hospital System |
2023-07-01 |
| NCT02481674 |
A Study in Subjects With Late Prodromal and Early Manifest Huntington’s Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Pepinemab (VX15/2503) |
https://ClinicalTrials.gov/show/NCT02481674 |
Active, not recruiting |
Vaccinex Inc. |
2020-05-31 |
| NCT02464293 |
A Pilot Evaluation of Mindfulness-based Cognitive Therapy for People With Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT02464293 |
Completed |
Lancaster University |
2018-01-31 |
| NCT02453061 |
A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT02453061 |
Active, not recruiting |
Institut National de la Santé Et de la Recherche Médicale, France |
2019-12-31 |
| NCT02336633 |
Resveratrol and Huntington Disease |
https://ClinicalTrials.gov/show/NCT02336633 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2019-10-31 |
| NCT02268617 |
Treadmill Walking in Individuals With Dementia With Lewy Bodies and Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT02268617 |
Completed |
Ohio State University |
2016-08-31 |
| NCT02252380 |
ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders |
https://ClinicalTrials.gov/show/NCT02252380 |
Active, not recruiting |
InSightec |
2021-12-31 |
| NCT02216474 |
Brain Stimulation in Movement Disorders |
https://ClinicalTrials.gov/show/NCT02216474 |
Completed |
Birmingham and Solihull Mental Health NHS Foundation Trust |
2018-09-30 |
| NCT02215616 |
A Clinical Study in Participants With Huntington’s Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod |
https://ClinicalTrials.gov/show/NCT02215616 |
Completed |
Teva Pharmaceutical Industries |
2018-06-19 |
| NCT02208934 |
Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers |
https://ClinicalTrials.gov/show/NCT02208934 |
Completed |
Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau |
2015-10-31 |
| NCT02197130 |
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT02197130 |
Completed |
Pfizer |
2016-09-30 |
| NCT02061722 |
[PETDE10] Imaging of PDE10A Enzyme Levels in Huntington’s Disease Gene Expansion Carriers and Healthy Controls With PET. |
https://ClinicalTrials.gov/show/NCT02061722 |
Completed |
CHDI Foundation, Inc. |
2016-05-31 |
| NCT01306929 |
Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease |
https://ClinicalTrials.gov/show/NCT01306929 |
Completed |
Prilenia |
2018-01-05 |
| NCT02006472 |
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT02006472 |
Completed |
Prilenia |
2016-07-31 |
| NCT01914965 |
Apathy Cure Through Bupropion in Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT01914965 |
Completed |
Charite University, Berlin, Germany |
2014-05-31 |
| NCT01897896 |
Alternatives for Reducing Chorea in Huntington Disease |
https://ClinicalTrials.gov/show/NCT01897896 |
Completed |
Teva Pharmaceutical Industries |
2017-08-21 |
| NCT01879267 |
Exercise Effects in Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT01879267 |
Completed |
University of Zurich |
2018-01-31 |
| NCT01842919 |
Dance and Huntington Disease |
https://ClinicalTrials.gov/show/NCT01842919 |
Completed |
Institut National de la Santé Et de la Recherche Médicale, France |
2015-07-28 |
| NCT01834911 |
Effect of Tetrabenazine on Stroop Interference in HD |
https://ClinicalTrials.gov/show/NCT01834911 |
Completed |
New York Medical College |
2018-01-01 |
| NCT01806896 |
Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT01806896 |
Completed |
Pfizer |
2015-01-31 |
| NCT01795859 |
First Time Use of SD-809 in Huntington Disease |
https://ClinicalTrials.gov/show/NCT01795859 |
Completed |
Teva Pharmaceutical Industries |
2014-12-05 |
| NCT01735981 |
The Effect of Video Game Exercise on Dynamic Balance and Gait in Individuals With Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT01735981 |
Completed |
Ohio State University |
2010-11-30 |
| NCT01696708 |
Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease |
https://ClinicalTrials.gov/show/NCT01696708 |
Completed |
Institut National de la Santé Et de la Recherche Médicale, France |
2015-11-30 |
| NCT01602900 |
Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT01602900 |
Completed |
GlaxoSmithKline |
2012-04-12 |
| NCT01590888 |
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease |
https://ClinicalTrials.gov/show/NCT01590888 |
Completed |
Prana Biotechnology Limited |
2013-07-31 |
| NCT01573819 |
A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278 |
https://ClinicalTrials.gov/show/NCT01573819 |
Completed |
GlaxoSmithKline |
2012-04-02 |
| NCT01521832 |
Escalating Dose Study in Healthy Volunteers With SEN0014196 |
https://ClinicalTrials.gov/show/NCT01521832 |
Completed |
Siena Biotech S.p.A. |
2010-05-31 |
| NCT01521585 |
A Phase II Safety and Tolerability Study With SEN0014196 |
https://ClinicalTrials.gov/show/NCT01521585 |
Completed |
Siena Biotech S.p.A. |
2012-10-31 |
| NCT01502046 |
Neuroprotection by Cannabinoids in Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT01502046 |
Completed |
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal |
2012-06-30 |
| NCT01485965 |
A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease |
https://ClinicalTrials.gov/show/NCT01485965 |
Completed |
Siena Biotech S.p.A. |
2012-11-30 |
| NCT01485952 |
An Exploratory Clinical Trial in Early Stage Huntington’s Disease Patients With SEN0014196 |
https://ClinicalTrials.gov/show/NCT01485952 |
Completed |
Siena Biotech S.p.A. |
2011-11-30 |
| NCT01458470 |
A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease |
https://ClinicalTrials.gov/show/NCT01458470 |
Completed |
University of British Columbia |
2012-08-31 |
| NCT01412151 |
Creatine Safety & Tolerability in Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT01412151 |
Completed |
Massachusetts General Hospital |
2011-11-30 |
| NCT01411163 |
Premanifest Huntington’s Disease Extension Study II: Creatine Safety & Tolerability |
https://ClinicalTrials.gov/show/NCT01411163 |
Completed |
Massachusetts General Hospital |
2013-05-31 |
| NCT01411150 |
Premanifest Huntington’s Disease: Creatine Safety & Tolerability Extension Study |
https://ClinicalTrials.gov/show/NCT01411150 |
Completed |
Massachusetts General Hospital |
2012-09-30 |
| NCT01359774 |
31P-MRS and Huntington Disease |
https://ClinicalTrials.gov/show/NCT01359774 |
Completed |
Institut National de la Santé Et de la Recherche Médicale, France |
2012-04-30 |
| NCT01357681 |
Effects of EGCG (Epigallocatechin Gallate) in Huntington’s Disease (ETON-Study) |
https://ClinicalTrials.gov/show/NCT01357681 |
Completed |
Charite University, Berlin, Germany |
2015-05-31 |
| NCT01339130 |
Assessment of Social-emotional Functioning in Neurological Diseases |
https://ClinicalTrials.gov/show/NCT01339130 |
Completed |
Centre Hospitalier Universitaire, Amiens |
2013-06-30 |
| NCT04400331 |
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease |
https://ClinicalTrials.gov/show/NCT04400331 |
Enrolling by invitation |
Neurocrine Biosciences |
2023-07-31 |
| NCT04120493 |
Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington Disease |
https://ClinicalTrials.gov/show/NCT04120493 |
Recruiting |
UniQure Biopharma B.V. |
2022-12-31 |
| NCT04071639 |
Symptomatic Therapy for Patients With Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT04071639 |
Recruiting |
Second Affiliated Hospital, School of Medicine, Zhejiang University |
2024-12-31 |
| NCT04012411 |
Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT04012411 |
Recruiting |
University Hospital, Montpellier |
2022-07-31 |
| NCT03980938 |
Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease |
https://ClinicalTrials.gov/show/NCT03980938 |
Recruiting |
EIP Pharma Inc |
2020-06-30 |
| NCT03854019 |
Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT03854019 |
Recruiting |
The University of Texas Health Science Center, Houston |
2019-11-01 |
| NCT03842969 |
An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington’s Disease Patients Who Participated in Prior Roche and Genentech Sponsored Studies |
https://ClinicalTrials.gov/show/NCT03842969 |
Recruiting |
Hoffmann-La Roche |
2024-06-19 |
| NCT03787758 |
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington’s Disease - Part B |
https://ClinicalTrials.gov/show/NCT03787758 |
Completed |
Sage Therapeutics |
2019-10-07 |
| NCT02418546 |
Electronic-health Application To Measure Outcomes REmotely Clinical Trial |
https://ClinicalTrials.gov/show/NCT02418546 |
Completed |
Massachusetts General Hospital |
2017-12-31 |
| NCT03764215 |
Nilotinib in Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT03764215 |
Recruiting |
Georgetown University |
2020-11-30 |
| NCT03761849 |
A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT03761849 |
Recruiting |
Hoffmann-La Roche |
2022-03-01 |
| NCT03713892 |
CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects |
https://ClinicalTrials.gov/show/NCT03713892 |
Recruiting |
Chong Kun Dang Pharmaceutical |
2020-12-31 |
| NCT03664804 |
Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT03664804 |
Active, not recruiting |
Hoffmann-La Roche |
2020-09-03 |
| NCT03575676 |
Efficacy and Safety of SOM3355 in Huntington’s Disease Chorea |
https://ClinicalTrials.gov/show/NCT03575676 |
Completed |
SOM Biotech SL |
2019-08-22 |
| NCT03515213 |
Safety and Efficacy of Fenofibrate as a Treatment for Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT03515213 |
Active, not recruiting |
University of California, Irvine |
2019-12-31 |
| NCT03417583 |
Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington’s Disease Patients |
https://ClinicalTrials.gov/show/NCT03417583 |
Recruiting |
Vanderbilt University Medical Center |
2021-12-31 |
| NCT00990613 |
A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin |
https://ClinicalTrials.gov/show/NCT00990613 |
Completed |
Pfizer |
2010-01-31 |
| NCT00988624 |
A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine) |
https://ClinicalTrials.gov/show/NCT00988624 |
Completed |
Pfizer |
2009-12-31 |
| NCT00980694 |
Bioavailability of Ubiquinol in Huntington Disease |
https://ClinicalTrials.gov/show/NCT00980694 |
Completed |
University of Rochester |
2012-07-31 |
| NCT00975481 |
A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users |
https://ClinicalTrials.gov/show/NCT00975481 |
Completed |
Pfizer |
2010-02-28 |
| NCT00970229 |
Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects. |
https://ClinicalTrials.gov/show/NCT00970229 |
Completed |
Institute for Neurodegenerative Disorders |
2015-04-30 |
| NCT00931073 |
A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers |
https://ClinicalTrials.gov/show/NCT00931073 |
Completed |
Pfizer |
2009-10-31 |
| NCT00920946 |
A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease |
https://ClinicalTrials.gov/show/NCT00920946 |
Completed |
Medivation, Inc. |
2011-07-31 |
| NCT00920699 |
Study in PRE-manifest Huntington’s Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL) |
https://ClinicalTrials.gov/show/NCT00920699 |
Completed |
Johns Hopkins University |
2012-03-31 |
| NCT00902889 |
Deep Brain Stimulation of the Globus Pallidus in Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT00902889 |
Completed |
Heinrich-Heine University, Duesseldorf |
2012-04-30 |
| NCT00870974 |
A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions |
https://ClinicalTrials.gov/show/NCT00870974 |
Completed |
Institute for Neurodegenerative Disorders |
2016-10-31 |
| NCT00831506 |
Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects |
https://ClinicalTrials.gov/show/NCT00831506 |
Completed |
Pfizer |
2009-05-31 |
| NCT00827034 |
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects |
https://ClinicalTrials.gov/show/NCT00827034 |
Completed |
Pfizer |
2009-04-30 |
| NCT00825084 |
A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects |
https://ClinicalTrials.gov/show/NCT00825084 |
Completed |
Pfizer |
2009-05-31 |
| NCT00824590 |
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function |
https://ClinicalTrials.gov/show/NCT00824590 |
Completed |
Pfizer |
2009-10-31 |
| NCT01882062 |
Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease |
https://ClinicalTrials.gov/show/NCT01882062 |
Completed |
Institut National de la Santé Et de la Recherche Médicale, France |
2013-07-31 |
| NCT02507284 |
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT02507284 |
Completed |
Azevan Pharmaceuticals |
2018-09-10 |
| NCT00788047 |
A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan |
https://ClinicalTrials.gov/show/NCT00788047 |
Completed |
Pfizer |
2009-01-31 |
| NCT00724048 |
A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT00724048 |
Completed |
Teva Pharmaceutical Industries |
2011-06-30 |
| NCT00665223 |
A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT00665223 |
Completed |
Teva Pharmaceutical Industries |
2011-06-30 |
| NCT00632645 |
Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride |
https://ClinicalTrials.gov/show/NCT00632645 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2017-04-28 |
| NCT00592995 |
Creatine Safety and Tolerability in Premanifest HD: PRECREST |
https://ClinicalTrials.gov/show/NCT00592995 |
Completed |
Massachusetts General Hospital |
2012-09-30 |
| NCT00497159 |
A Study of the Novel Drug Dimebon in Patients With Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT00497159 |
Completed |
Medivation, Inc. |
2008-06-30 |
| NCT00387270 |
Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT00387270 |
Completed |
Medivation, Inc. |
2007-03-31 |
| NCT00368849 |
Atomoxetine and Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT00368849 |
Completed |
University of Iowa |
2008-02-29 |
| NCT00277602 |
Riluzole in Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT00277602 |
Completed |
Sanofi |
2004-07-31 |
| NCT00277355 |
Pilot Study of Minocycline in Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT00277355 |
Completed |
Huntington Study Group |
2008-10-31 |
| NCT00271596 |
Citalopram to Enhance Cognition in HD |
https://ClinicalTrials.gov/show/NCT00271596 |
Completed |
University of Iowa |
2011-04-30 |
| NCT00219804 |
Efficacy and Safety of Tetrabenazine in Chorea |
https://ClinicalTrials.gov/show/NCT00219804 |
Completed |
Prestwick Pharmaceuticals |
NA |
| NCT00212316 |
Safety and Tolerability Study of Phenylbutyrate in Huntington’s Disease (PHEND-HD) |
https://ClinicalTrials.gov/show/NCT00212316 |
Completed |
University of Rochester |
NA |
| NCT00190450 |
MIG-HD: Multicentric Intracerebral Grafting in Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT00190450 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2013-12-31 |
| NCT00178360 |
Effects of Music Therapy on Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT00178360 |
Completed |
University of Rochester |
2008-12-31 |
| NCT00146211 |
TREND-HD - A Trial of Ethyl-EPA (Miraxionâ„¢) in Treating Mild to Moderate Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT00146211 |
Completed |
Amarin Neuroscience Ltd |
2007-08-31 |
| NCT00095355 |
Effects of Lithium and Divalproex`on Brain-Derived Neurotrophic Factor in Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT00095355 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00001930 |
Treatment of Huntington’s Chorea With Amantadine |
https://ClinicalTrials.gov/show/NCT00001930 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00029874 |
Minocycline in Patients With Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT00029874 |
Completed |
FDA Office of Orphan Products Development |
NA |
| NCT00026988 |
Creatine Therapy for Huntington’s Disease |
https://ClinicalTrials.gov/show/NCT00026988 |
Completed |
National Center for Complementary and Integrative Health (NCCIH) |
NA |